Article
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Hepatology (Baltimore, Md.) - 1 Jun 2013
Sulkowski Mark S, Asselah Tarik, Lalezari Jacob, Ferenci Peter, Fainboim Hugo, Leggett Barbara, Bessone Fernando, Mauss Stefan, Heo Jeong, Datsenko Yakov, Stern Jerry O, Kukolj George, Scherer Joseph, Nehmiz Gerhard, Steinmann Gerhard G, Böcher Wulf O
Abstract excerpt
UNLABELLED: Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once-daily (QD) dosing. Four hundred and twenty-nine HCV genotype (GT)-1 treatment-naïve patients without cirrhosis were randomized 1:1:2:2 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combination with placebo, faldaprevir 120 mg QD...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.